Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 412,600 shares, an increase of 53.4% from the September 30th total of 269,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 0.4 days. Currently, 3.3% of the company’s shares are short sold. Currently, 3.3% of the company’s shares are short sold. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 0.4 days.

Hoth Therapeutics Trading Down 1.4%

Shares of HOTH stock traded down $0.02 during trading hours on Monday, hitting $1.40. The company’s stock had a trading volume of 356,288 shares, compared to its average volume of 3,357,136. The company has a 50 day moving average of $1.52 and a 200 day moving average of $1.27. The stock has a market cap of $18.56 million, a PE ratio of -1.31 and a beta of 0.67. Hoth Therapeutics has a 12-month low of $0.66 and a 12-month high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.10. As a group, analysts anticipate that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Institutional Trading of Hoth Therapeutics

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC raised its stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 8.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,575 shares of the company’s stock after purchasing an additional 9,071 shares during the period. Geode Capital Management LLC owned 0.93% of Hoth Therapeutics worth $143,000 at the end of the most recent quarter. 7.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOTH has been the subject of several research reports. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research report on Monday, August 18th. Wall Street Zen raised shares of Hoth Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Hoth Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.50.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.